Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

Luigi Gargiuloa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information

Luciano Ibbaa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyCorrespondence[email protected]
View further author information

Matteo Biancoa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information

Sara Di Giulioa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information

Alfano Alfanoa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information

Ruggero Cascio Ingurgioa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information

Paola Facherisa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information

Chiara Peruginia Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information

Mario Valentia Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy

https://orcid.org/0000-0001-9140-9263 View further author information

Antonio Costanzoa Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy;b Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, ItalyView further author information

Alessandra Narcisia Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, ItalyView further author information

show all

Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date